Ionis Pharmaceuticals Inc

+0.07 (+0.16%)
Products, Regulatory

Ionis Announces Positive Topline Results From Phase 2B Clinical Study Of Fesomersen, A Potential Novel Anti-Thrombotic Treatment

Published: 07/28/2022 11:49 GMT
Ionis Pharmaceuticals Inc (IONS) - Ionis Announces Positive Topline Results From Phase 2b Clinical Study of Fesomersen, a Potential Novel Anti-thrombotic Treatment.
Ionis Pharmaceuticals Inc - Phase 2b Re-thinc Esrd Study of Fesomersen Met Its Primary Endpoint in Patients With End-stage Renal Disease on Hemodialysis.
Ionis Pharmaceuticals Inc - Fesomersen Demonstrated Substantial and Statistically Significant Reductions in Factor Xi Activity Levels.
Ionis Pharmaceuticals Inc - Fesomersen, a Novel Factor Xi Antisense Inhibitor Designed to Prevent Thrombosis, Was Safe and Well-tolerated in Study With Up to 48-week.